Genmab AS News - GE9

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma Company...

Completion of Share Buy-back Program

Completion of Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 27, 2024 – Genmab A/S (Nasdaq: GMAB) announces that...

EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Company Announcement...

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 24, 2024 – Genmab A/S (Nasdaq: GMAB...

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; June 18, 2024 – Genmab A/S...

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 17, 2024 – Genmab A/S (Nasdaq: GMAB...

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; June 12, 2024 – Genmab A/S...

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company...

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 10, 2024 – Genmab A/S (Nasdaq: GMAB...

Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference Media Release COPENHAGEN, Denmark;...

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 3, 2024 – Genmab A/S (Nasdaq: GMAB). On...

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and...

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in...

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2...

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 27, 2024 – Genmab A/S (Nasdaq: GMAB). On...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Genmab AS (GE9)

Empower your portfolio: Real-time discussions and actionable trading ideas.

GE9 News

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

Completion of Share Buy-back Program

EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Transactions in Connection with Share Buy-back Program

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions in Connection with Share Buy-back Program

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Transactions in Connection with Share Buy-back Program

Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

Transactions in Connection with Share Buy-back Program

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Transactions in Connection with Share Buy-back Program

GE9 Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Genmab AS (GE9) News

Genmab AS (GE9)

Empower your portfolio: Real-time discussions and actionable trading ideas.

GE9 News

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

Completion of Share Buy-back Program

EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Transactions in Connection with Share Buy-back Program

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions in Connection with Share Buy-back Program

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Transactions in Connection with Share Buy-back Program

Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

Transactions in Connection with Share Buy-back Program

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Transactions in Connection with Share Buy-back Program

GE9 Discussion

Your Recent History